Laboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Suita City, Osaka, Japan.
Laboratory of Clinical Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita City, Osaka, Japan.
J Cell Physiol. 2022 May;237(5):2539-2549. doi: 10.1002/jcp.30724. Epub 2022 Mar 21.
Because mammalian cardiomyocytes largely cease to proliferate immediately after birth, the regenerative activity of the heart is limited. To date, much effort has been made to clarify the regulatory mechanism of cardiomyocyte proliferation because the amplification of cardiomyocytes could be a promising strategy for heart regenerative therapy. Recently, it was reported that the inhibition of glycogen synthase kinase (GSK)-3 promotes the proliferation of neonatal rat cardiomyocytes (NRCMs) and human iPS cell-derived cardiomyocytes (hiPSC-CMs). Additionally, Yes-associated protein (YAP) induces cardiomyocyte proliferation. The purpose of this study was to address the importance of YAP activity in cardiomyocyte proliferation induced by GSK-3 inhibitors (GSK-3Is) to develop a novel strategy for cardiomyocyte amplification. Immunofluorescent microscopic analysis using an anti-Ki-67 antibody demonstrated that the treatment of NRCMs with GSK-3Is, such as BIO and CHIR99021, increased the ratio of proliferative cardiomyocytes. YAP was localized in the nuclei of more than 95% of cardiomyocytes, either in the presence or absence of GSK-3Is, indicating that YAP was endogenously activated. GSK-3Is increased the expression of β-catenin and promoted its translocation into the nucleus without influencing YAP activity. The knockdown of YAP using siRNA or pharmacological inhibition of YAP using verteporfin or CIL56 dramatically reduced GSK-3I-induced cardiomyocyte proliferation without suppressing β-catenin activation. Interestingly, the inhibition of GSK-3 also induced the proliferation of hiPSC-CMs under sparse culture conditions, where YAP was constitutively activated. In contrast, under dense culture conditions, in which YAP activity was suppressed, the proliferative effects of GSK-3Is on hiPSC-CMs were not detected. Importantly, the activation of YAP by the knockdown of α-catenin restored the proproliferative activity of GSK-3Is. Collectively, YAP activation potentiates the GSK-3I-induced proliferation of cardiomyocytes. The blockade of GSK-3 in combination with YAP activation resulted in remarkable amplification of cardiomyocytes.
由于哺乳动物的心肌细胞在出生后不久就基本停止增殖,因此心脏的再生能力有限。迄今为止,人们已经做了大量努力来阐明心肌细胞增殖的调控机制,因为心肌细胞的扩增可能是心脏再生治疗的一种很有前途的策略。最近,有报道称,糖原合酶激酶(GSK)-3 的抑制可促进新生大鼠心肌细胞(NRCM)和人诱导多能干细胞衍生的心肌细胞(hiPSC-CMs)的增殖。此外,Yes 相关蛋白(YAP)可诱导心肌细胞增殖。本研究旨在探讨 GSK-3 抑制剂(GSK-3Is)诱导的心肌细胞增殖中 YAP 活性的重要性,以开发一种新的心肌细胞扩增策略。用抗 Ki-67 抗体进行免疫荧光显微镜分析表明,GSK-3Is,如 BIO 和 CHIR99021,处理 NRCM 可增加增殖性心肌细胞的比例。YAP 定位于心肌细胞的核内,无论是在存在或不存在 GSK-3Is 的情况下,这表明 YAP 是内源性激活的。GSK-3Is 增加了β-catenin 的表达,并促进其向核内转位,而不影响 YAP 活性。用 siRNA 敲低 YAP 或用 verteporfin 或 CIL56 药理学抑制 YAP 可显著减少 GSK-3I 诱导的心肌细胞增殖,而不抑制 β-catenin 激活。有趣的是,在稀疏培养条件下,GSK-3 的抑制也诱导 hiPSC-CMs 的增殖,在这种条件下,YAP 被组成性激活。相比之下,在密集培养条件下,YAP 活性受到抑制,GSK-3Is 对 hiPSC-CMs 的促增殖作用未被检测到。重要的是,用α-连环蛋白的敲低激活 YAP 恢复了 GSK-3Is 的促增殖活性。总之,YAP 的激活增强了 GSK-3I 诱导的心肌细胞增殖。GSK-3 的阻断与 YAP 的激活相结合导致心肌细胞的显著扩增。